Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

AI-generated analysis

📈 Amgen stock has advanced 35% year-to-date in 2026, reaching a price of $440.84 and securing second place among major drugmakers.

💊 The company markets more than 20 products, with 17 annualizing above $1 billion in sales, providing a stable revenue foundation.

🔬 Key franchises include Repatha for cholesterol, EVENITY for osteoporosis, TEPEZZA for thyroid eye disease, and IMDELLTRA for small cell lung cancer.

🦠 Amgen operates a substantial biosimilars business featuring products such as AMJEVITA, MVASI, PAVBLU, and WEZLANA.

🚀 The pipeline is anchored by MariTide, an antibody-peptide conjugate in Phase 3 development for obesity with monthly or less frequent dosing.

🧬 Additional pipeline candidates include olpasiran for cardiovascular outcomes, xaluritamig for prostate cancer, and dazodalibep for Sjögren's disease.

📊 Amgen is a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, offering broad market exposure.

🏥 The company addresses severe asthma with TEZSPIRE and continues to innovate across diverse therapeutic areas.

Bullish Signals
  • Amgen stock has advanced 35% year-to-date in 2026, reaching a price of $440.84 and securing second place among major drugmakers.
  • The company markets more than 20 products, with 17 annualizing above $1 billion in sales, providing a stable revenue foundation.
  • Key franchises include Repatha for cholesterol, EVENITY for osteoporosis, TEPEZZA for thyroid eye disease, and IMDELLTRA for small cell lung cancer.
  • Amgen operates a substantial biosimilars business featuring products such as AMJEVITA, MVASI, PAVBLU, and WEZLANA.
  • The pipeline is anchored by MariTide, an antibody-peptide conjugate in Phase 3 development for obesity with monthly or less frequent dosing.
  • Additional pipeline candidates include olpasiran for cardiovascular outcomes, xaluritamig for prostate cancer, and dazodalibep for Sjögren's disease.
  • Amgen is a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, offering broad market exposure.
  • The company addresses severe asthma with TEZSPIRE and continues to innovate across diverse therapeutic areas.
Full Analysis
In the first half of 2026, Amgen (NASDAQ:AMGN) has emerged as a strong performer within the large-cap pharmaceutical sector, advancing its stock price by 35% year-to-date to reach $440.84. While trailing Merck's superior 44% gain, Amgen maintains a solid second-place position among peers like Pfizer, which has risen 14%. The article highlights that Amgen's performance is driven by a robust portfolio of over 20 products, with 17 annualizing above $1 billion in sales, positioning it as a resilient player despite the sector's heavy focus on obesity drugs. Amgen's financial strength is anchored by key franchises including Repatha for cholesterol management, EVENITY for osteoporosis, and TEPEZZA for thyroid eye disease. The company has successfully expanded its oncology capabilities with IMDELLTRA for small cell lung cancer and BLINCYTO, while also addressing severe asthma with TEZSPIRE. Additionally, Amgen leverages a substantial biosimilars business featuring products like AMJEVITA and MVASI, diversifying its revenue streams beyond its core monoclonal antibody offerings. Looking forward, Amgen is strategically advancing its pipeline with MariTide, an antibody-peptide conjugate currently in Phase 3 development for obesity that features a convenient monthly or less frequent dosing schedule. The company is also exploring candidates such as olpasiran for cardiovascular outcomes and xaluritamig for prostate cancer. As a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen offers investors exposure to a diversified mix of established therapies and innovative late-stage developments.